OssDsign AB (publ) publishes Year-end Report 2022

A year of sustained high growth and demonstrated scalability

The fourth quarter in figures

• Net sales amounted to TSEK 19,929 (9,174)
• Loss after taxes amounted to TSEK 31,948 (28,726). 
• Earnings per share was SEK -0.5 (-0.5).
• Cash flow from current operations was TSEK –25,687 (-20,456).

 
The full year in figures

• Net sales amounted to TSEK 56,985 (31,726).
• Loss after taxes amounted to TSEK 99,388 (94,077).
• Earnings per share was SEK –1.7 (-1.9).
• Cash flow from current operations was TSEK –88,975 (-89,629).

 
Important events during the fourth quarter

• OssDsign extends the Catalyst portfolio and launches new product for additional surgical procedures. 
• OssDsign reaches milestone of 100 patients in its PROPEL registry ahead of time. 
• First post-market surveillance data of OssDsign Catalyst® shows zero precent device related complication rate. 
• OssDsign completes a directed new share issue and raised proceeds of approximately SEK 65.6 million. 
• Post-market surveillance continues to show low observed complication rates with OssDsign Cranial PSI.

 
Important events after the end of the fourth quarter

• First-in-patient case report of OssDsign Catalyst shows complete spinal fusion 6 months post-surgery.
• OssDsign reaches milestone of 500 patients treated with OssDsign Catalyst in the U.S.
• OssDsign Catalyst 1cc is launched and available in the U.S. market.

 
The Year-end 2022 results will also be presented at an investor webcast today February 21st at 11:00 CET. The webcast can be accessed via the following link https://www.finwire.tv/webcast/ossdsign/2022-q4/ or via the OssDsign website.  

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: [email protected]
 
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: [email protected].
 
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
 

This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08:00 CET on February 21, 2023.